Determination of the role of lutetium-PSMA and other drugs aimed at PSA in prostate cancer
Автор: Solodky V.A., Pavlov A.Yu., Fomin D.K., Dzidzaria A.G., Gafanov R.A., Aivazov M.T., Oskarev A.V., Khoroshevskaya I.V.
Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr
Рубрика: Обзоры, лекции
Статья в выпуске: 2 т.22, 2022 года.
Бесплатный доступ
Lutetium-117-PSMA-617 (LuPSMA) radioligand therapy affects prostate cancer by selectively delivering beta-particle radiation to cells expressing high levels of prostate-specific membrane antigen (PSMA). Prostate-specific membrane antigen (PSMA) is a transmembrane protein with high expression in most prostate cancer cells compared to normal prostate cells and other healthy tissues, and therefore PSMA is an excellent target for prostate cancer therapy. Numerous clinical trials confirm the use of LuPSMA for the treatment of PSMA-positive prostate cancer detected with PSMA-PET.
Lutetium-117-psma-617, radioligand therapy, metastatic castration-resistant prostate cancer, skeletal bone metastases, pet-ct with psma
Короткий адрес: https://sciup.org/149141236
IDR: 149141236
